Molecular mechanisms underlying disruptions in brain glucose uptake and metabolism, linked with cognitive decline in Alzheimer’s disease (AD) patients, are only partially understood. This study investigated how soluble amyloid beta (sAβ) peptides affect glucose transport at the blood-brain barrier (BBB), the primary portal for glucose entry into the brain. We demonstrated that [18F]-fluorodeoxyglucose (18FDG) uptake is reduced in sAβ overproducing APP,PS1 transgenic mice compared to wild-type mice. Moreover, the influx rate of 18FDG decreased in sAβ40 or sAβ42 pre-infused mice, highlighting the inhibitory effect of sAβ peptides on glucose transport at the BBB. Consistently, the expression of GLUT1, the primary glucose transporter at the BBB, is reduced in polarized human cerebral microvascular endothelial cell (hCMEC/D3) monolayers upon exposure to sAβ peptides and in Aβ-laden cerebral vasculature in vivo. The study further examined the influence of sAβ on the insulin-AKT pathway, known to regulate glucose uptake through modulation of thioredoxin-interacting protein (TXNIP) expression. Results showed that sAβ peptides suppress AKT phosphorylation and reduce GLUT1 expression by upregulating TXNIP levels in hCMEC/D3 monolayers. Co-incubation of resveratrol with sAβ peptides reduced TXNIP expression and rectified reductions in GLUT1 expression. In summary, toxic sAβ impairs BBB glucose transport by disrupting the insulin/AKT/TXNIP axis.
KadryHNooraniBCuculloL.A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS2020;
17: 69.
2.
ZlokovicBV.Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci2011;
12: 723–738.
3.
ChamplinAKDorrDLGatesAH.Determining the stage of the estrous cycle in the mouse by the appearance of the vagina. Biol Reprod1973;
8: 491–494.
4.
MergenthalerPLindauerUDienelGA, et al.
Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci2013;
36: 587–597.
5.
CunnaneSCCourchesne-LoyerASt-PierreV, et al.
Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann N Y Acad Sci2016;
1367: 12–20.
6.
SokoloffL.Energetics of functional activation in neural tissues. Neurochem Res1999;
24: 321–329.
7.
CornfordEMHymanSCornfordME, et al.
Interictal seizure resections show two configurations of endothelial Glut1 glucose transporter in the human blood-brain barrier. J Cereb Blood Flow Metab1998;
18: 26–42.
8.
SimpsonIAVannucciSJDeJosephMR, et al.
Glucose transporter asymmetries in the bovine blood-brain barrier. J Biol Chem2001;
276: 12725–12729.
9.
KuboYOhtsukiSUchidaY, et al.
Quantitative determination of luminal and abluminal membrane distributions of transporters in porcine brain capillaries by plasma membrane fractionation and quantitative targeted proteomics. J Pharm Sci2015;
104: 3060–3068.
10.
CornfordEMHymanSSwartzBE.The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab1994;
14: 106–112.
11.
PardridgeWMBoadoRJFarrellCR.Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative Western blotting and in situ hybridization. J Biol Chem1990;
265: 18035–18040.
12.
FarrellCLPardridgeWM.Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci U S A1991;
88: 5779–5783.
13.
LippoldtAKnieselULiebnerS, et al.
Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spontaneously hypertensive rat blood-brain barrier endothelial cells. Brain Res2000;
885: 251–261.
14.
StewartPAHayakawaKFarrellCL.Quantitation of blood-brain barrier ultrastructure. Microsc Res Tech1994;
27: 516–527.
15.
McAllisterMSKrizanac-BengezLMacchiaF, et al.
Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res2001;
904: 20–30.
16.
MosconiL.Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging2005;
32: 486–510.
17.
OssenkoppeleRvan der FlierWMZwanMD, et al.
Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology2013;
80: 359–365.
18.
ProtasHDChenKLangbaumJBS, et al.
Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-Middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol2013;
70: 320–325.
19.
MosconiLMisturRSwitalskiR, et al.
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging2009;
36: 811–822.
20.
MosconiL.Glucose metabolism in normal aging and Alzheimer’s disease: methodological and physiological considerations for PET studies. Clin Transl Imaging2013;
1
21.
LandauSMHarveyDMadisonCM, Alzheimer’s Disease Neuroimaging Initiativeet al.
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;
75: 230–238.
22.
HendrixRDOuYDavisJE, et al.
Alzheimer amyloid-beta- peptide disrupts membrane localization of glucose transporter 1 in astrocytes: implications for glucose levels in brain and blood. Neurobiol Aging2021;
97: 73–88.
23.
MerliniMMeyerEPUlmann-SchulerA, et al.
Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol2011;
122: 293–311.
24.
AllenAMessierC.Plastic changes in the astrocyte GLUT1 glucose transporter and beta-tubulin microtubule protein following voluntary exercise in mice. Behav Brain Res2013;
240: 95–102.
25.
ChoeiriCStainesWMikiT, et al.
Glucose transporter plasticity during memory processing. Neuroscience2005;
130: 591–600.
26.
ZellerKRahner-WelschSKuschinskyW.Distribution of Glut1 glucose transporters in different brain structures compared to glucose utilization and capillary density of adult rat brains. J Cereb Blood Flow Metab1997;
17: 204–209.
27.
SimpsonIAChunduKRDavies-HillT, et al.
Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol1994;
35: 546–551.
28.
MooradianADChungHCShahGN.GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging1997;
18: 469–474.
29.
KalariaRNHarikSI.Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem1989;
53: 1083–1088.
30.
HorwoodNDaviesDC.Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer’s disease. Virchows Arch1994;
425: 69–72.
31.
LoweVJWeigandSDSenjemML, et al.
Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology2014;
82: 1959–1967.
32.
OkerekeOIXiaWSelkoeDJ, et al.
Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol2009;
66: 1247–1253.
33.
MarkRJPangZGeddesJW, et al.
Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci1997;
17: 1046–1054.
34.
PrapongTBussJHsuWH, et al.
Amyloid beta-peptide decreases neuronal glucose uptake despite causing increase in GLUT3 mRNA transcription and GLUT3 translocation to the plasma membrane. Exp Neurol2002;
174: 253–258.
35.
RautSPatelRPervaizI, et al.
Abeta peptides disrupt the barrier integrity and glucose metabolism of human induced pluripotent stem cell-derived brain microvascular endothelial cells. Neurotoxicology2022;
89: 110–120.
36.
LiuYLiuFGrundke-IqbalI, et al.
Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol2011;
225: 54–62.
37.
SteenETerryBMRiveraEJ, et al.
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease – is this type 3 diabetes?J Alzheimers Dis2005;
7: 63–80.
38.
Jauch-CharaKFriedrichARezmerM, et al.
Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes2012;
61: 2261–2268.
39.
MullinsRJDiehlTCChiaCW, et al.
Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease. Front Aging Neurosci2017;
9: 118.
40.
WengenackTMWhelanSCurranGL, et al.
Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain. Neuroscience2000;
101: 939–944.
41.
McLeanACValenzuelaNFaiS, et al.
Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J Vis Exp2012;
15: e4389.
42.
Percie Du SertNHurstVAhluwaliaA, et al.
The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol2020;
18: e3000410.
43.
ShardaNAhlschwedeKMCurranGL, et al.
Distinct uptake kinetics of Alzheimer disease amyloid-beta 40 and 42 at the Blood-Brain barrier endothelium. J Pharmacol Exp Ther2021;
376: 482–490.
44.
HambergLMHunterGJAlpertNM, et al.
The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?J Nucl Med1994;
35: 1308–1312.
45.
HunterGJHambergLMAlpertNM, et al.
Simplified measurement of deoxyglucose utilization rate. J Nucl Med1996;
37: 950–955.
46.
EberlSAnayatARFultonRR, et al.
Evaluation of two population-based input functions for quantitative neurological FDG PET studies. Eur J Nucl Med1997;
24: 299–304.
47.
ShiozakiTSadatoNSendaM, et al.
Noninvasive estimation of FDG input function for quantification of cerebral metabolic rate of glucose: optimization and multicenter evaluation. J Nucl Med2000;
41: 1612–1618.
48.
FangYHKaoTLiuRS, et al.
Estimating the input function non-invasively for FDG-PET quantification with multiple linear regression analysis: simulation and verification with in vivo data. Eur J Nucl Med Mol Imaging2004;
31: 692–702.
49.
PatlakCSBlasbergRGFenstermacherJD.Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab1983;
3: 1–7.
50.
PatlakCSBlasbergRG.Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab1985;
5: 584–590.
51.
ZhouALSwaminathanSKCurranGL, et al.
Apolipoprotein A-I crosses the blood-brain barrier through clathrin-independent and cholesterol-mediated endocytosis. J Pharmacol Exp Ther2019;
369: 481–488.
52.
MotallebnejadPAzarinSM.Chemically defined human vascular laminins for biologically relevant culture of hiPSC-derived brain microvascular endothelial cells. Fluids Barriers CNS2020;
17: 54.
53.
AgyareEKLeonardSRCurranGL, et al.
Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer’s disease amyloid-beta proteins in the cerebral vasculature. Mol Pharm2013;
10: 1557–1565.
54.
SwaminathanSKAhlschwedeKMSarmaV, et al.
Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab2018;
38: 904–918.
55.
SwaminathanSKZhouALAhlschwedeKM, et al.
High-density lipoprotein mimetic peptide 4F efficiently crosses the blood-brain barrier and modulates amyloid-beta distribution between brain and plasma. J Pharmacol Exp Ther2020;
375: 308–316.
56.
DavisJXuFDeaneR, et al.
Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem2004;
279: 20296–20306.
57.
WuNZhengBShaywitzA, et al.
AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell2013;
49: 1167–1175.
58.
BegMZhangWMcCourtAC, et al.
ATGL activity regulates GLUT1-mediated glucose uptake and lactate production via TXNIP stability in adipocytes. J Biol Chem2021;
296: 100332.
59.
WaldhartANDykstraHPeckAS, et al.
Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. Cell Rep2017;
19: 2005–2013.
60.
GaliCCFanaee-DaneshEZandl-LangM, et al.
Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-beta in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. Mol Cell Neurosci2019;
99: 103390.
61.
UkoNEGunerOFMatesicDF, et al.
Akt pathway inhibitors. Curr Top Med Chem2020;
20: 883–900.
62.
NicholsonRMKusneYNowakLA, et al.
Regional cerebral glucose uptake in the 3xTG model of Alzheimer’s disease highlights common regional vulnerability across AD mouse models. Brain Res2010;
1347: 179–185.
63.
AndersenJVChristensenSKAldanaBI, et al.
Alterations in cerebral cortical glucose and glutamine metabolism precedes amyloid plaques in the APPswe/PSEN1dE9 mouse model of Alzheimer’s disease. Neurochem Res2017;
42: 1589–1598.
64.
HuangJvan ZijlPCMHanX, et al.
Altered d-glucose in brain parenchyma and cerebrospinal fluid of early Alzheimer’s disease detected by dynamic glucose-enhanced MRI. Sci Adv2020;
6: eaba3884.
65.
NiwaKKazamaKYounkinSG, et al.
Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis2002;
9: 61–68.
66.
MacdonaldIRDeBayDRReidGA, et al.
Early detection of cerebral glucose uptake changes in the 5XFAD mouse. Curr Alzheimer Res2014;
11: 450–460.
67.
LuoFRustayNREbertU, et al.
Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer’s disease. Neurobiol Aging2012;
33: 933–944.
68.
LebenbergJHerardASDuboisA, et al.
Automated indexation of metabolic changes in Alzheimer’s mice using a voxel-wise approach combined to an MRI-based 3D digital atlas. Annu Int Conf IEEE Eng Med Biol Soc2010;
2010: 5636–5639.
69.
PoisnelGHérardA-SEl Tannir El TayaraN, et al.
Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer’s disease. Neurobiol Aging2012;
33: 1995–2005.
70.
RojasSHeranceJRGispertJD, et al.
In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging2013;
34: 1790–1798.
71.
SanchetiHPatilIKanamoriK, et al.
Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer’s disease and the effect of lipoic acid: a 13C-NMR study. J Cereb Blood Flow Metab2014;
34: 1749–1760.
72.
KnightEMVerkhratskyALuckmanSM, et al.
Hypermetabolism in a triple-transgenic mouse model of Alzheimer’s disease. Neurobiol Aging2012;
33: 187–193.
73.
BouterCBouterY. (
18)F-FDG-PET in mouse models of Alzheimer’s disease. Front Med (Lausanne)2019;
6: 71.
74.
OmtriRSThompsonKJTangX, et al.
Differential effects of Alzheimer’s disease Abeta40 and 42 on endocytosis and intraneuronal trafficking. Neuroscience2018;
373: 159–168.
75.
ShankarGMLiSMehtaTH, et al.
Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med2008;
14: 837–842.
76.
AllamanIMagistrettiPJ.Brain energy metabolism. In: SquireLRBergDBloomFE, et al. (eds) Fundamental neuroscience.
Academic Press:
San Diego, 2013, pp. 261–284.
77.
Cruz HernándezJCBrackoOKersbergenCJ, et al.
Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. Nat Neurosci2019;
22: 413–420.
78.
WinklerEANishidaYSagareAP, et al.
GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci2015;
18: 521–530.
79.
SzablewskiL.Glucose transporters in brain: In health and in Alzheimer’s disease. JAD2016;
55: 1307–1320.
80.
PatchingSG.Glucose transporters at the Blood-Brain barrier: Function, regulation and gateways for drug delivery. Mol Neurobiol2017;
54: 1046–1077.
81.
ParikhHCarlssonEChutkowWA, et al.
TXNIP regulates peripheral glucose metabolism in humans. PLoS Med2007;
4: e158.
82.
JiangXPangYWeiZhaoS, et al.
Thioredoxin-interacting protein regulates glucose metabolism and improves the intracellular redox state in bovine oocytes during in vitro maturation. Am J Physiol Endocrinol Metab2020;
318: E405–E416.
83.
MirhadiERoufogalisBDBanachM, et al.
Resveratrol: mechanistic and therapeutic perspectives in pulmonary arterial hypertension. Pharmacol Res2021;
163: 105287.
84.
MousaSAGallatiCSimoneT, et al.
Dual targeting of the antagonistic pathways mediated by Sirt1 and TXNIP as a putative approach to enhance the efficacy of anti-aging interventions. Aging (Albany NY)2009;
1: 412–424.
85.
BedaridaTBaronSVibertF, et al.
Resveratrol decreases TXNIP mRNA and protein nuclear expressions with an arterial function improvement in old mice. J Gerontol A Biol Sci Med Sci2016;
71: 720–729.
86.
LinJ-NLinVC-HRauK-M, et al.
Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem2010;
58: 1584–1592.
87.
LiLIsmaelSNasoohiS, et al.
Thioredoxin-interacting protein (TXNIP) associated NLRP3 inflammasome activation in human Alzheimer’s disease brain. J Alzheimers Dis2019;
68: 255–265.
88.
HongSYYuFXLuoY, et al.
Oncogenic activation of the PI3K/akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. Cell Signal2016;
28: 377–383.
89.
MakinoshimaHTakitaMSaruwatariK, et al.
Signaling through the phosphatidylinositol 3-Kinase (PI3K)/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. J Biol Chem2015;
290: 17495–17504.
90.
WangH-MLuY-JHeL, et al.
HPV16 E6/E7 promote the translocation and glucose uptake of GLUT1 by PI3K/AKT pathway via relieving miR-451 inhibitory effect on CAB39 in lung cancer cells. Ther Adv Chronic Dis2020;
11: 2040622320957143.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
